Patient with agammaglobulinemia produces anti-SARS-CoV-2 reactive T-cells after CoronaVac vaccine

[1]  J. Orange,et al.  New primary immunodeficiencies 2021 context and future , 2021, Current opinion in pediatrics.

[2]  Mark J. Ponsford,et al.  COVID-19 and X-linked agammaglobulinemia (XLA) – insights from a monogenic antibody deficiency , 2021, Current opinion in allergy and clinical immunology.

[3]  L. Notarangelo,et al.  Antibody responses to the SARS-CoV-2 vaccine in individuals with various inborn errors of immunity , 2021, Journal of Allergy and Clinical Immunology.

[4]  Xilong Deng,et al.  Protective humoral and cellular immune responses to SARS-CoV-2 persist up to 1 year after recovery , 2021, Nature Communications.

[5]  Yixiao Lin,et al.  Decline in neutralising antibody responses, but sustained T‐cell immunity, in COVID‐19 patients at 7 months post‐infection , 2021, Clinical & translational immunology.

[6]  F. Krammer A correlate of protection for SARS-CoV-2 vaccines is urgently needed , 2021, Nature Medicine.

[7]  S. Zaffina,et al.  SARS-CoV-2 Vaccine Induced Atypical Immune Responses in Antibody Defects: Everybody Does their Best , 2021, Journal of Clinical Immunology.

[8]  F. Cinetto,et al.  Vaccination in PADs , 2021, Vaccines.

[9]  N. Freund,et al.  Immunogenicity of Pfizer-BioNTech COVID-19 vaccine in patients with inborn errors of immunity , 2021, Journal of Allergy and Clinical Immunology.

[10]  Christopher A. Lazarski,et al.  Robust Antibody and T Cell Responses to SARS-CoV-2 in Patients with Antibody Deficiency , 2021, Journal of Clinical Immunology.

[11]  A. Fiore-Gartland,et al.  Evidence for antibody as a protective correlate for COVID-19 vaccines , 2021, Vaccine.

[12]  I. Quinti,et al.  Clinical management of patients with primary immunodeficiencies during the COVID-19 pandemic , 2021, Expert review of clinical immunology.

[13]  Mark J. Ponsford,et al.  Increased Respiratory Viral Detection and Symptom Burden Among Patients with Primary Antibody Deficiency: Results from the BIPAD Study , 2020, The Journal of Allergy and Clinical Immunology: In Practice.

[14]  M. Yılmaz,et al.  Clinical and genetic profiles of patients with X-linked agammaglobulinemia from southeast Turkey: Novel mutations in BTK gene. , 2019, Allergologia et immunopathologia.

[15]  F. Bonilla,et al.  Vaccination in Primary Immunodeficiency Disorders. , 2016, The journal of allergy and clinical immunology. In practice.

[16]  E. Timmers,et al.  X-linked agammaglobulinemia. , 1991, Clinical immunology and immunopathology.